European Association for the Study of Diabetes

Loading the player ...

EASD 2015 - An SGLT-2 antagonist reduces mortality in type 2 diabetes

Paly Button
You can select your prefered subtitle language by using the  CC  button in the player control bar.

Go down to other videos
Facebook share button Share on Twitter linkedID button
Send to a collegue

Empagliflozine, an SGLT-2 antagonist, on top of the classic treatment of type 2 diabetes patients at high risk is associated with a reduction in the HbA1c level and the cardiovascular and total mortality.

Related Videos

Partnership

ASCO 2014 - Advances in Breast Cancer at the 2014 ASCO meeting

ASCO 2014 - Advances in Breast Cancer at the 2014 ASCO meeting
Url
Go to

Best of Science in Nutrition 2013: Yogurt for a healthier diet (EB & IUNS 2013)

Best of Science in Nutrition 2013: Yogurt for a healthier diet (EB & IUNS 2013)
Url
Go to
with
Danone Institute International